A downtrend has been apparent in Cue Biopharma, Inc. (CUE) lately. While the stock has lost 8.7% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its ...

Today is shaping up negative for Cue Biopharma, Inc. (NASDAQ:CUE) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Both revenue and earnings per ...

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Cue Biopharma (CUE – Research Report), with a price target of $2.00. Reni Benjamin has given his Buy ...

CAMBRIDGE, Mass., April 25, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to ...

Novel approach to CAR-T therapies. Multiple potential indications provide ample opportunities for the company. Partnership with Merck is encouraging, but very early. Pipeline is too young to ...